FBV_01 tear substitute with ancillary medicinal substance
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for FBV_01 tear substitute with ancillary medicinal substance, covering 2026-02-17 to 2026-02-17. Get the full timeline:
Most recent: Clinical Trial Update: Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hyaluronic Acid 0.3% (FBV_01) vs Hyaluronic Acid 0.3% in Subjects in the Treatment From Moderate to Severe DED [NA]